KVUE
Kenvue, Inc.
September 9, 2026 · market open
- Rarity
- 1.45
- Peak move
- −3.91%
- Float cap
- $35.2B
Kenvue is a global consumer health company offering a portfolio of self care, skin health and beauty, and essential health products. Its science-backed brands include Aveeno, Band-Aid, Johnson's, Listerine, Neutrogena, Tylenol, and Zyrtec, among others. The company markets its products to consumers across more than 165 countries worldwide.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the moveinstitutional_flowCarmignac Gestion increased its Kenvue stake by 166.8% in Q2 2026, adding 262,858 shares to hold 420,432 shares worth about $8.0 million per its quarterly 13F filing.
- Key event
clinical_readoutKenvue presented clinical data at PAINWeek 2026 showing TYLENOL with Naproxen provides long-lasting relief in post-surgical pain, including Phase 3 dental and bunionectomy studies and Phase 2 data superior to an opioid combination; the product is coming to U.S. retailers.
- Key event
institutional_flowAmundi acquired 5,392,413 Kenvue shares in Q2 2026, increasing its holding by 41.2% per its quarterly 13F filing.
- Key event
executive_remarkAt a Barclays conference on September 8, 2026, Kimberly-Clark discussed its pending acquisition of Kenvue, expecting $500 million in incremental operating profit from revenue synergies, reinvesting $300 million, divestitures under 1% of combined revenue, and deal close in Q4 2026.
institutional_flowReadystate Asset Management LP purchased 200,000 shares of Kenvue in Q2 2026, raising its position by 18.9% to 1.26 million shares worth about $24.0 million per its 13F filing.